MEMPHIS, Tenn.--(BUSINESS WIRE)--In2Bones Global, Inc. today announced the global launch of the AlloAid BioNail™, an engineered, sterile allograft implant designed to provide rigid, stable fixation during reconstructive surgery of the hand and foot.
Derived from strong cortical allograft, the AlloAid BioNail provides osteoconductive properties to encourage bone remodeling and healing, thus enabling a more natural fixation. In2Bones’ innovative design – a tapered point and multiple, contoured wedge facets – eases insertion, anchors the implant into a fusion site, and acts as a compressive force to aid fixation.
Unlike traditional solid metallic implants that provide no biologic benefit (metal implants do not remodel, requiring bone to heal around the device), the new AlloAid BioNail allografts are resorbed gradually by the surrounding bone. This eliminates many post-operative complications and greatly reduces the need for the implant to be removed – both common problems with metal implants. The natural, engineered allograft also makes the BioNail viable for patients with known metal allergies.
For surgeons, the new implant offers several advantages. “The BioNail is preferred over metal implants for fixating bunions for a few reasons,” says Dr. Amber Shane of Orlando Foot & Ankle Clinic. “Native bone incorporation is made possible by osteoconductive and osteoinductive properties at the fusion site, and, the implant’s radiolucent nature allows for better monitoring of bone healing during the perioperative period. In addition, the simple surgical steps save valuable OR time compared to placing screws.”
“As surgeons, we are always thinking about options for patients should further surgery be needed. With the BioNail, revision osteotomies are possible because no surgical voids are created,” Shane explains.
The AlloAid BioNail implant is supplied sterile, in various sizes, with single-use surgical instrument kits.
Allograft implants have had a long and successful clinical history, and are currently used in multiple applications and thousands of procedures annually. In2Bones is the market leader in engineered sterile allografts, with additional applications for hammertoe surgery and DIP finger joint fusions.
The AlloAid BioNail is the sixth In2Bones sterile allograft product commercialized under the brand name AlloAid. It demonstrates In2Bones’ commitment to expanding the extremities market by launching innovative technological advancements to improve surgical outcomes and patient care.
For more information about In2Bones Global, Inc. extremity products, please visit www.In2bones.com.
Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.In2bones.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current view of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” and other similar terms. The company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting the business, including increased competition, technical obsolescence, regulatory issues, general economic conditions, and other risks.